Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Inclusion Criteria: * Histologically or cytologically confirmed malignant melanoma and clinical evidence of metastatic disease to the brain. Mucosal and ocular melanomas are included. * Newly developed inoperable brain metastases without associated hemorrhage or midline shift. * Inoperable or metastatic extra cranial stage III or IV disease. * Diagnostic quality MRI of the brain or if contraindicated then contrast CT scan of the head performed within 28 days prior to registration. * Measurable metastases to the brain, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>10 mm in the brain MRI/CT scan. * CT scan chest, abdomen and pelvis or PET CT scan performed within 28 days of study registration. For disease outside the brain, tumors must be \> 10 mm by CT scan. * Prior therapy allowed but no prior therapy with nab-paclitaxel, paclitaxel, temozolomide, DTIC or bevacizumab. * Bevacizumab may not be initiated until 4 weeks after surgical resection or radiation therapy completion. * Age 18 or older. * Pre-existing peripheral neuropathy must have \< Grade 2 (per CTCAE 4.0) at the time of registration. * Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential. * Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment. * ECOG Performance status 0-1. * Estimated life expectancy of greater than 2 months. * Patients must have adequate organ function as defined below (these must be evaluated within 14 days prior to registration): * leukocytes \>3,000/mcL * absolute neutrophil count \>1,500/mcL * platelets \>100,000/mcL * Hemoglobin \>9.0 g/dL * AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit * Alkaline phosphatase \<2.5 X institutional upper limit * Total bilirubin \<1.5 X institutional upper limit of normal (unless associated with Gilbert's syndrome) * serum creatinine \< 1.5 mg/dL OR 1.5 x institutional normal * LDH there is no restriction * INR \<1.5 PTT WNL * Urine protein (UPC) ratio 1.0 OR * Urine dipstick for proteinuria. Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Able to render informed consent. Exclusion Criteria: * Prior surgical resection for brain metastases. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, nab-paclitaxel or temozolomide. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, unstable angina pectoris, untreated cardiac arrhythmia and peripheral vascular disease. * History of myocardial infarction or unstable angina within 6 months prior to Day 1. * History of stroke or transient ischemic attack within 6 months prior to Day 1. * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study screening. * Serious, non-healed wound, ulcer, or bone fracture. * History of hepatitis B, C or HIV. * Uncontrolled hypertension or chronic renal disease. No known bleeding diathesis. * Known hypersensitivity to human albumin. * Surgery within 4 weeks of study registration. Must be fully recovered and fully healed from any prior surgery. * Patients having chemotherapy or extra cranial radiotherapy within 4 weeks prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to the completion of study screening. * Evidence of other concurrent active malignancy. * Pregnant or nursing. * Not be receiving any other investigational agent.